<DOC>
	<DOCNO>NCT00858377</DOCNO>
	<brief_summary>This first-in-human study AMG 900 conduct two part : dose escalation dose expansion . The dose escalation part study aim evaluate safety , tolerability PK oral AMG 900 subject advance solid tumor . Up 50 subject may enrol dose escalation . The dose expansion part study consist 42 subject three taxane-resistant tumor type . The dose AMG 900 dependent upon data dose escalation part study</brief_summary>
	<brief_title>A Phase 1 First-in-Human Study Evaluating AMG 900 Advanced Solid Tumors</brief_title>
	<detailed_description>G-CSF must start day 5 , 1 day last day AMG 900 continue neutrophile &gt; 1000 day 12 , mean 2 day reinduction .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Complement Factor H</mesh_term>
	<criteria>Men woman ≥ 18 year old Part 1 Dose Escalation : advanced solid tumor refractory standard treatment standard therapy available subject refuse standard therapy Part 1 Dose Escalation : Measurable evaluable disease per RECIST guideline Part 2 Dose Expansion : Taxaneresistant tumor ( defined refractory progression within 6 month discontinue paclitaxel docetaxel ) prespecified histology Part 2 Dose Expansion : Measurable disease per RECIST guideline Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Life expectancy &gt; 3 month , opinion investigator Willing provide exist and/or future paraffinembedded tumor sample Part 1 Dose Escalation : must tumor tissue accessible biopsy fine needle aspiration ( FNA ) must consent undergo biopsy tumor ( subject nonaccelerated phase ) Ability take oral medication Competent sign date Institutional Review Board approve inform consent form Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin &gt; 9 g/dL Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 1.5 x upper limit normal ( ULN ) Serum creatinine &lt; 2.0 mg/dL Calculated creatinine clearance ≥ 50 ml/min AST &lt; 2.5 x ULN ( liver bone metastasis present , ≤ 5 x ULN ) ALT &lt; 2.5 x ULN ( liver bone metastasis present , ≤ 5 x ULN ) Alkaline phosphatase &lt; 2.0 x ULN ( liver bone metastasis present , ≤ 5 x ULN ) Total bilirubin &lt; 1.5 x ULN Active parenchymal brain metastasis . Subjects brain metastasis resect received radiation therapy end least 4 week prior study day 1 eligible meet follow criterion : ) residual neurological symptom grade &lt; 1 ; b ) dexamethasone requirement ; c ) followup MRI show new lesion appear Prior bone marrow transplant ( autologous allogeneic ) History presence hematological malignancy History bleed diathesis Myocardial infarction within 6 month study day 1 , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina , unstable cardiac arrhythmia require medication Active peptic ulcer disease Gastrointestinal ( GI ) tract disease cause inability take oral medication , malabsorption syndrome , requirement intravenous alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( eg , Crohn 's disease , ulcerative colitis ) Active infection require intravenous ( IV ) antibiotic within 2 week study enrollment ( day 1 ) Known positive test HIV Active chronic hepatitis B hepatitis C infection , determine serologic test Unresolved toxicity prior antitumor therapy , define resolved Common Terminology Criteria Adverse Events ( CTCAE ) grade 0 1 , level dictate eligibility criterion exception alopecia Antitumor therapy within 28 day study day 1 ; concurrent use hormone deprivation therapy hormonerefractory prostate cancer breast cancer permit Treatment immune modulators include , limited , corticosteroid , cyclosporine tacrolimus within two week prior enrollment Therapeutic palliative radiation therapy within two week study day 1 Systemic anticoagulation therapy , include warfarin , within 28 day day 1 Prior treatment aurora inhibitor Prior participation investigational study ( drug device ) within 28 day study day 1 Major surgery within 28 day study day 1 Any comorbid medical disorder may increase risk toxicity , opinion investigator sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>First Human</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Aurora kinase inhibitor</keyword>
	<keyword>Open-label</keyword>
	<keyword>Oncology</keyword>
</DOC>